Navigation Links
WHI Findings Published in JAMA Do Not Affect Clinical Guidance for the Appropriate Use of Hormone Therapy
Date:3/4/2008

Hormone Therapy Remains an Important Option for Women Seeking Relief of

Menopausal Symptoms

COLLEGEVILLE, Pa., March 4 /PRNewswire-FirstCall/ -- Observational follow-up data from the Women's Health Initiative (WHI) study published today in the Journal of the American Medical Association (JAMA) provide little new insight into the appropriate use of hormone therapy when it is prescribed to symptomatic, newly menopausal women. Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), believes that hormone therapy, when used appropriately, remains a good health care choice to relieve moderate to severe menopausal symptoms for millions of women seeking treatment.

"Health care professionals and women should be cautious about drawing generalized conclusions with regard to the benefits and risks of hormone therapy based upon an observational follow-up of the WHI. The WHI was conducted in older women and was designed to assess the risks and benefits of hormone therapy for the prevention of heart disease," says Gary L. Stiles, M.D., Executive Vice President and Chief Medical Officer, Wyeth Pharmaceuticals.

The women who participated in the WHI study were predominantly non-symptomatic and were on average 63 years of age, which is more than a decade past the average onset of menopause. In recent years, reanalysis of WHI findings has repeatedly shown that the risks associated with hormone therapy use in this older study population were not consistently shared across all outcomes by the younger subset of women who are more representative of a newly menopausal, hormone therapy user.

"Selectively releasing information contained in the WHI database, without providing the full context of the data assesse
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
2. Topline Findings from Comparative Analysis of INVEGA(TM) and Quetiapine in Schizophrenia to be Postered at the 20th Annual U.S. Psychiatric and Mental Health Congress
3. Clinical Study Findings Show Safety and Procedure Success for TopSpin IntraVascular MRI Catheter for the Coronary Arteries
4. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
5. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
6. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
7. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
8. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
9. Vasogens Research Published in European Journal of Neuroscience
10. The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis
11. Newly Published EPA RCRA Method 6800 Supports AIT Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... Calif. , March 3, 2015 AtheroNova Inc. ... AtheroNova Operations, Inc., filed voluntary petitions under Chapter 11 of ... District of California , Santa ... 2015. The Company,s Chapter 11 cases are expected to be ... including a Bankruptcy Court supervised asset sale process, for all ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 Becht ... today that it has acquired The CECON Group, ... the transaction were not announced. , Becht Engineering ... the energy sector including oil and gas production, ... fossil and nuclear power sectors. The company has ...
(Date:3/3/2015)... CAMBRIDGE, Mass. (PRWEB) March 03, 2015 ... driven by Semantic Web technology, today announced that it ... ‘100 Companies That Matter in Knowledge Management.’ , ... select group of colleagues, analysts and system integrators who ... and delivery of the right information to the right ...
(Date:3/3/2015)... Mar. 03, 2015 Research and Markets ... PharmaBiotech,s new report "RNAi - Technologies, Markets and ... Because of its ability to silence any gene once ... the research tool to discriminate gene function. After the ... designed to target every gene in the genome and ...
Breaking Biology Technology:AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 2AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 3AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 4Cambridge Semantics Named to KMWorld’s 2015 ‘100 Companies That Matter in Knowledge Management’ 2Global RNAi Market Report 2015 - Technologies, Markets and Companies 2014-2024 2Global RNAi Market Report 2015 - Technologies, Markets and Companies 2014-2024 3
... May 19, 2010 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) ... New York on Wednesday, May 26, 2010 at 3:00 ... Casdin , vice president, finance at Amylin Pharmaceuticals, will provide a corporate overview. ... The presentation will be webcast live ...
... MOUNTAIN VIEW, Calif. , May 19 ... , Ph.D., the Company,s President and Chief Executive Officer ... Of The Year® 2010 Award in Northern California ... program recognizes entrepreneurs who demonstrate extraordinary success in the ...
... , CALGARY , May 19 /PRNewswire-FirstCall/ ... announced today that following submission to the U.S. Food ... initiating a U.S. Phase I study of REOLYSIN(R) in ... + Irinotecan) in patients with oxaliplatin refractory/intolerant Kras mutant ...
Cached Biology Technology:Amylin Pharmaceuticals to Present at the 2010 Citi Investment Research Global Healthcare Conference 2ChemoCentryx President and CEO, Thomas J. Schall, Ph.D., Named Ernst & Young Entrepreneur Of The Year 2010 Award Finalist in Northern California 2ChemoCentryx President and CEO, Thomas J. Schall, Ph.D., Named Ernst & Young Entrepreneur Of The Year 2010 Award Finalist in Northern California 3ChemoCentryx President and CEO, Thomas J. Schall, Ph.D., Named Ernst & Young Entrepreneur Of The Year 2010 Award Finalist in Northern California 4Oncolytics Biotech(R) Inc. Announces Phase I Colorectal Cancer Study 2Oncolytics Biotech(R) Inc. Announces Phase I Colorectal Cancer Study 3Oncolytics Biotech(R) Inc. Announces Phase I Colorectal Cancer Study 4
(Date:2/5/2015)... New Market Research Reports Title ... To 2020 has Been Added to GrandViewReseach.com Report Database ... to reach USD 5.10 billion by 2020, according to ... cameras help identify the site of tissue damage in ... demand in medical imaging applications. They have been extensively ...
(Date:2/5/2015)... MOUNTAIN VIEW, Calif. , Feb. 3, 2015 ... screen printer technology, demand from industries such as ... the global market for surface mount technology (SMT) ... manual equipment to automatic control will push the ... glue dispensers will remain steady as glue dispensers ...
(Date:1/22/2015)... , Jan. 13, 2015  Today, FreeWavz ( ... launched its crowdfunding campaign on Fundable, https://www.fundable.com/freewavz ... build of production capacity to meet customer demand. ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
Breaking Biology News(10 mins):IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2
... sound counterintuitive, but LSU Associate Professor of Chemistry Robert Cook ... materials found in the environment, including soils, can either get ... or NSF, was so impressed with his efforts that the ... the NSF CAREER award. "One of the biggest questions ...
... You can teach an old drug new chemotherapy tricks. ... blood cancers but ineffective against solid tumors, packaged it ... type of breast cancer prevalent in young women, particularly ... trioxide, long part of the arsenal of ancient Chinese ...
... Eurofins MWG Operon, an expert in next generation sequencing ... capture, together with Genomatix Software GmbH, a leading company ... announce that they have developed a complete human exome ... "We are pleased to offer this comprehensive service for ...
Cached Biology News:LSU researcher looks for new ways to keep a dirty situation clean 2LSU researcher looks for new ways to keep a dirty situation clean 3New arsenic nanoparticle blocks aggressive breast cancer 2New arsenic nanoparticle blocks aggressive breast cancer 3Eurofins MWG Operon and Genomatix developed most complete human exome array 2
Zebrafish Ephrin-B2 Biotinylated Affinity Purified PAb...
Collected from 8-12 week old New Zealand or Californian rabbits. Aseptically collected and processed to minimize hemolytic activity. Pricing: $60/unit for 1 - 10 units...
One-step, microplate or cuvet, colorimetric, detection range 0.3 g/dL to 5 g/dL. Procedure: 5 min....
...
Biology Products: